ProShare Advisors’s Zevra Therapeutics ZVRA Stock Holding History

ProShare Advisors’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,594	Closed	-$98.7K	–	2036
2026 Q1	$98.7K	Sell	10,594 -2,075	-16%	-$18.7K	﹤0.01%	1707
2025 Q4	$114K	Buy	12,669 +1,390	+12%	+$13.1K	﹤0.01%	1850
2025 Q3	$107K	Sell	11,279 -1,892	-14%	-$19K	﹤0.01%	1831
2025 Q2	$116K	Sell	13,171 -851	-6%	-$6.91K	﹤0.01%	1852
2025 Q1	$105K	Sell	14,022 -3,403	-20%	-$27K	﹤0.01%	1825
2024 Q4	$145K	Buy	+17,425	New	+$149K	﹤0.01%	1977
2024 Q3	–	Sell	-4,871	Closed	-$23.9K	–	2125
2024 Q2	$23.9K	Buy	+4,871	New	+$23.1K	﹤0.01%	1802
2022 Q1	–	Sell	-11,452	Closed	-$100K	–	2312
2021 Q4	$100K	Buy	+11,452	New	+$102K	﹤0.01%	2207
2016 Q3	–	Sell	-681	Closed	-$43K	–	1521
2016 Q2	$43K	Buy	681 +16	+2%	+$2.63K	﹤0.01%	1558
2016 Q1	$154K	Sell	665 -61	-8%	-$14.8K	﹤0.01%	1465
2015 Q4	$231K	Buy	+726	New	+$197K	﹤0.01%	1456

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

ProShare Advisors's ZVRA Position: Q2 2026 in Review

ProShare Advisors sold out of Zevra Therapeutics (ZVRA) in Q2 2026, closing a stake of 10,594 shares — an estimated $98.7K sold.

ProShare Advisors first reported a position in ZVRA in Q4 2015 and held it in 11 quarters. The position peaked at $231K in Q4 2015. 158 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

ProShare Advisors reported no remaining Zevra Therapeutics position as of Q2 2026 after selling out during the quarter.
ProShare Advisors sold 10,594 Zevra Therapeutics shares in Q2 2026, an estimated $98.7K.
ProShare Advisors first reported a position in Zevra Therapeutics in Q4 2015 and held it in 11 quarters.
ProShare Advisors's Zevra Therapeutics position peaked at $231K in Q4 2015.
158 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.